Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Trichomoniasis

Essential points for quick revision.

Saved on this device
!
Exclude upper-tract and pregnancy emergencies

Pelvic pain, cervical motion tenderness, fever, sepsis, pregnancy pain or heavy bleeding is not explained by uncomplicated trichomoniasis and may indicate PID, ectopic pregnancy or another acute condition.

Action: Assess pregnancy and haemodynamic status, examine for upper-tract disease, obtain microbiological samples without delaying empirical PID or emergency treatment, and involve gynaecology or maternity care promptly.

Synopsis

Diagnose Trichomonas vaginalis with an appropriate test, use effective systemic metronidazole including in pregnancy, and prevent reinfection through concurrent partner care.

  • Trichomonas vaginalis is a sexually transmitted protozoan infection; many people are asymptomatic, while vaginitis can produce offensive yellow-green discharge, soreness, dysuria and a raised vaginal pH.
  • Use a validated NAAT when available because symptoms and wet-mount microscopy lack sensitivity; a negative wet mount does not exclude infection.
  • Give oral metronidazole 400–500 mg twice daily for seven days; the multidose course is more effective than a single 2 g dose and topical metronidazole is inadequate.

Key red flags

Pelvic or lower abdominal pain with cervical motion, uterine or adnexal tenderness requires assessment and empirical treatment for PID.

Pregnancy with pain, bleeding, contractions, fluid loss or reduced fetal movement needs urgent maternity assessment rather than routine vaginitis follow-up.

Fever, hypotension, vomiting or peritonism suggests complicated pelvic infection or another acute abdominal diagnosis.

Persistent infection after verified adherence and partner treatment requires specialist review for reinfection, test timing and possible nitroimidazole resistance. Treat current sexual partners concurrently, offer testing for chlamydia, gonorrhoea, syphilis and HIV, and avoid sex for at least one week and until the patient and partners have completed treatment and follow-up.

Ulceration, significant contact bleeding or a mass requires examination for herpes, syphilis, trauma or neoplasia.

Upper-tract features

Pelvic pain, fever, abnormal bleeding and cervical or adnexal tenderness indicate possible PID and demand broader immediate care.

Investigation priorities

01
Trichomonas NAATFirst step

Detect T. vaginalis sensitively from a vaginal or other specimen validated by the local laboratory.

Management branches

CONFIRMTest the discharge syndrome

A patient presents with discharge, odour, irritation, dysuria or notification as a trichomonas contact.

  1. Ask privately about onset, discharge, pain, bleeding, urinary symptoms, pregnancy possibility, exposure sites, prior treatment and partner symptoms.
  2. Examine the vulva and cervix when appropriate, assess upper-tract tenderness, and obtain a validated trichomonas NAAT with wider STI samples.

Key medicines

Metronidazole multidoseTake 400 to 500 mg orally twice daily for seven days for uncomplicated trichomoniasis.Review warfarin, lithium, liver disease and neurological symptoms; use in pregnancy when indicated and follow current product advice about alcohol.
Metronidazole single doseA 2 g oral single dose is an alternative when adherence to multidose therapy is not achievable.Avoid high-dose therapy in pregnancy where possible, anticipate gastrointestinal intolerance, and do not use topical gel as a substitute.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom